Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholder Deficit

v3.20.2
Condensed Consolidated Statement of Changes in Stockholder Deficit - USD ($)
Common Stock [Member]
Additional Paid-In-Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2018 $ 670 $ 58,407,257 $ (61,943,318) $ (3,535,391)
Balance, shares at Dec. 31, 2018 669,967      
Common stock grants to independent directors $ 8 262,492 262,500
Common stock grants to independent directors, shares 8,137      
Common stock grants to service providers $ 1 14,399 14,400
Common stock grants to service providers, shares 562      
Stock based compensation - options 257,875 257,875
Restricted stock issuances $ 8 244,992 245,000
Restricted stock issuances, shares 8,169      
Issuance of warrants attached to convertible notes 141,435 141,435
Extinguishment of derivative liability upon repayment of convertible note      
Net loss (3,650,740) (3,650,740)
Balance at Sep. 30, 2019 $ 687 59,328,450 (65,594,058) (6,264,921)
Balance, shares at Sep. 30, 2019 686,835      
Balance at Jun. 30, 2019 $ 684 59,044,605 (64,160,432) (5,115,143)
Balance, shares at Jun. 30, 2019 683,731      
Common stock grants to independent directors $ 3 87,497 87,500
Common stock grants to independent directors, shares 2,917      
Common stock grants to service providers 3,338 3,338
Common stock grants to service providers, shares 187      
Stock based compensation - options 84,875 84,875
Issuance of warrants attached to convertible notes 108,135 108,135
Net loss (1,433,626) (1,433,626)
Balance at Sep. 30, 2019 $ 687 59,328,450 (65,594,058) (6,264,921)
Balance, shares at Sep. 30, 2019 686,835      
Balance at Dec. 31, 2019 $ 688 59,836,818 (67,036,355) (7,198,849)
Balance, shares at Dec. 31, 2019 687,564      
Common stock grants to independent directors $ 18 56,232 56,250
Common stock grants to independent directors, shares 17,708      
Stock based compensation - options 207,187 207,187
Issuance of warrants attached to convertible notes 303,630 303,630
Warrants granted to independent directors 225,000 225,000
Common stock grants to convertible note holders $ 81 532,131 532,212
Common stock grants to convertible note holders, shares 81,409      
Beneficial conversion feature issued on convertible notes 141,391 141,391
Revaluation of notes payable discounts due to modification of conversion price (271,998) (271,998)
Extension fee for convertible note $ 6 24,994 25,000
Extension fee for convertible note, shares 6,250      
Extinguishment of derivative liability upon repayment of convertible note 458,977 458,977
Stock retirement $ (28) 28
Stock retirement, shares (27,777)      
Net loss (4,057,541) (4,057,541)
Balance at Sep. 30, 2020 $ 765 61,514,390 (71,093,896) (9,578,741)
Balance, shares at Sep. 30, 2020 765,154      
Balance at Jun. 30, 2020 $ 753 61,101,987 (69,739,565) (8,636,825)
Balance, shares at Jun. 30, 2020 752,654      
Common stock grants to independent directors $ 6 18,744 18,750
Common stock grants to independent directors, shares 6,250      
Stock based compensation - options 50,312 50,312
Issuance of warrants attached to convertible notes 300,853 300,853
Warrants granted to independent directors 75,000 75,000
Revaluation of notes payable discounts due to modification of conversion price (57,500) (57,500)
Extension fee for convertible note $ 6 24,994 25,000
Extension fee for convertible note, shares 6,250      
Net loss (1,354,331) (1,354,331)
Balance at Sep. 30, 2020 $ 765 $ 61,514,390 $ (71,093,896) $ (9,578,741)
Balance, shares at Sep. 30, 2020 765,154